Unicycive Therapeutics (UNCY) Enterprise Value (2021 - 2026)
Unicycive Therapeutics' (UNCY) quarterly Enterprise Value came in at -$54.6 million in Q1 2026, down 176.12% YoY from $71.7 million in Q1 2025, and down 32.27% on a QoQ basis from -$41.3 million in Q4 2025.
Unicycive Therapeutics (UNCY) Enterprise Value (2021 - 2026) Analysis & Trends
Unicycive Therapeutics (UNCY) has 6 years of Enterprise Value data on file, last reported at -$54.6 million in Q1 2026.
- Quarterly Enterprise Value fell 176.12% year-over-year to -$54.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$54.6 million (down 176.12% YoY) and the FY2025 annual result came in at -$41.3 million, down 57.86% from the prior year.
- Enterprise Value slipped to -$54.6 million in Q1 2026, from -$41.3 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$455000.0 in Q4 2022 to a low of -$54.6 million in Q1 2026.
- A 5-year average of -$25.2 million and a median of -$22.3 million in 2025 frame the typical range for Enterprise Value.
- The widest YoY moves for Enterprise Value: up 97.26% in 2022, down 1057200.0% in 2022.
- Tracing UNCY's Enterprise Value over 5 years: stood at -$455000.0 in 2022, then sank by 2032.09% to -$9.7 million in 2023, then slumped by 169.48% to -$26.1 million in 2024, then plunged by 57.86% to -$41.3 million in 2025, then plunged by 32.27% to -$54.6 million in 2026.
- The last three Enterprise Value figures came in at -$54.6 million (Q1 2026), -$41.3 million (Q4 2025), and -$42.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Unicycive Therapeutics | 147.24 Mn | 147.24 Mn | - | -61.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -61.43 Mn |
| Mar 31, 2026 | -54.59 Mn |
| Dec 31, 2025 | -41.27 Mn |
| Sep 30, 2025 | -42.70 Mn |
| Jun 30, 2025 | -22.33 Mn |
| Mar 31, 2025 | -19.77 Mn |
| Dec 31, 2024 | -26.14 Mn |
| Sep 30, 2024 | -32.35 Mn |
| Jun 30, 2024 | -41.78 Mn |
| Mar 31, 2024 | -48.93 Mn |
| Dec 31, 2023 | -9.70 Mn |
| Sep 30, 2023 | -14.35 Mn |
| Jun 30, 2023 | -18.82 Mn |
| Mar 31, 2023 | -24.33 Mn |
| Dec 31, 2022 | -455,000.00 |
| Sep 30, 2022 | -7.01 Mn |
| Jun 30, 2022 | -10.57 Mn |
| Mar 31, 2022 | -13.62 Mn |
| Dec 31, 2021 | -16.58 Mn |
| Sep 30, 2021 | -18.01 Mn |